Immunotherapy for alzheimer's disease

Martin Farlow, Jared R. Brosch

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The immune system plays a significant role in Alzheimer disease (AD). β-Amyloid deposition in the cortex is thought to be an initiating event in AD and the widely believed amyloid hypothesis proposes removal of amyloid may delay disease progression. Human trials of active or passive immune agents have failed to show benefit and increased adverse events of vasogenic edema and microhemorrhages. Evidence suggests the illness may be too advanced by the time patients are symptomatic with dementia. Future directions include better understanding of how and where immunotherapies should be targeted and treating patients at earlier stages of the illness.

Original languageEnglish
Pages (from-to)869-878
Number of pages10
JournalNeurologic Clinics
Volume31
Issue number3
DOIs
StatePublished - Aug 2013

Fingerprint

Amyloid
Immunotherapy
Alzheimer Disease
Dementia
Disease Progression
Immune System
Edema

Keywords

  • β-amyloid
  • Alzheimer disease
  • Immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Immunotherapy for alzheimer's disease. / Farlow, Martin; Brosch, Jared R.

In: Neurologic Clinics, Vol. 31, No. 3, 08.2013, p. 869-878.

Research output: Contribution to journalArticle

Farlow, Martin ; Brosch, Jared R. / Immunotherapy for alzheimer's disease. In: Neurologic Clinics. 2013 ; Vol. 31, No. 3. pp. 869-878.
@article{db55aadeb2904f8db6b14116e611eac6,
title = "Immunotherapy for alzheimer's disease",
abstract = "The immune system plays a significant role in Alzheimer disease (AD). β-Amyloid deposition in the cortex is thought to be an initiating event in AD and the widely believed amyloid hypothesis proposes removal of amyloid may delay disease progression. Human trials of active or passive immune agents have failed to show benefit and increased adverse events of vasogenic edema and microhemorrhages. Evidence suggests the illness may be too advanced by the time patients are symptomatic with dementia. Future directions include better understanding of how and where immunotherapies should be targeted and treating patients at earlier stages of the illness.",
keywords = "β-amyloid, Alzheimer disease, Immunotherapy",
author = "Martin Farlow and Brosch, {Jared R.}",
year = "2013",
month = "8",
doi = "10.1016/j.ncl.2013.03.012",
language = "English",
volume = "31",
pages = "869--878",
journal = "Neurologic Clinics",
issn = "0733-8619",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Immunotherapy for alzheimer's disease

AU - Farlow, Martin

AU - Brosch, Jared R.

PY - 2013/8

Y1 - 2013/8

N2 - The immune system plays a significant role in Alzheimer disease (AD). β-Amyloid deposition in the cortex is thought to be an initiating event in AD and the widely believed amyloid hypothesis proposes removal of amyloid may delay disease progression. Human trials of active or passive immune agents have failed to show benefit and increased adverse events of vasogenic edema and microhemorrhages. Evidence suggests the illness may be too advanced by the time patients are symptomatic with dementia. Future directions include better understanding of how and where immunotherapies should be targeted and treating patients at earlier stages of the illness.

AB - The immune system plays a significant role in Alzheimer disease (AD). β-Amyloid deposition in the cortex is thought to be an initiating event in AD and the widely believed amyloid hypothesis proposes removal of amyloid may delay disease progression. Human trials of active or passive immune agents have failed to show benefit and increased adverse events of vasogenic edema and microhemorrhages. Evidence suggests the illness may be too advanced by the time patients are symptomatic with dementia. Future directions include better understanding of how and where immunotherapies should be targeted and treating patients at earlier stages of the illness.

KW - β-amyloid

KW - Alzheimer disease

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84881025664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881025664&partnerID=8YFLogxK

U2 - 10.1016/j.ncl.2013.03.012

DO - 10.1016/j.ncl.2013.03.012

M3 - Article

VL - 31

SP - 869

EP - 878

JO - Neurologic Clinics

JF - Neurologic Clinics

SN - 0733-8619

IS - 3

ER -